Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized, Study to Evaluate the Efficacy and Safety of Two Doses of AUR101 in Patients With Moderate-to-Severe Psoriasis

NCT04207801 is registered in ClinicalTrials.gov with Aurigene Discovery Technologies Limited as lead sponsor.

NCT NCT04207801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04207801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized, Study to Evaluate the Efficacy and Safety of Two Doses of AUR101 in Patients With Moderate-to-Severe Psoriasis
Lead sponsor
Aurigene Discovery Technologies Limited
Phase
Phase 2
Overall status
Completed
Start date
January 21, 2020
Completion date
April 15, 2021
Enrollment
90 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic plaque-type psoriasis